NCT06083103

Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)

Name: Clinical Trial NCT06083103
Creator: Institut de cancérologie Strasbourg Europe
Keywords: Cervical Cancer, 18-FDG PET-MRI, diagnostic test, clinical trial, France

Contribution of PET/MRI in Locally Advanced Cervical Cancer

Institut de cancérologie Strasbourg Europe·ClinicalTrials.gov·diagnostic testNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Cervical Cancer
Drug/Device/Intervention: 18-FDG PET-MRI
Study type: Observational
Intervention type: diagnostic test

Sponsor & location

Primary sponsor: Institut de cancérologie Strasbourg Europe
Location: Strasbourg, France

Timeline & enrollment

Phase: N/A
Start date: Oct 02, 2023
End date: Dec 31, 2025
Enrollment: 50 participants

Primary outcome

Compare performances of PET/MRI and PET/CT in the detection of lumbar aortic lymph node metastases in cervical cancer patients with tumors graded IB2 to IVA stage

Summary

[18 F]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is particularly promising. Its usefulness seems obvious in certain tumor types, but its place in the staging of cervical cancers has never been explored in a prospective trial to our knowledge.  Previously, a comparative retrospective study from 2009 found a better sensitivity of PET fused to diagnostic MRI images compared to PET/CT (positron emission tomography/computed tomography) in the detection of metastatic lymph nodes (54 and 44% respectively). It was an a posteriori fusion of images, from images acquired by PET-CT.

ICD-10 classifications

Severe cervical dysplasia, not elsewhere classifiedMild cervical dysplasiaModerate cervical dysplasiaCarcinoma in situ: Cervix, unspecifiedCervical root disorders, not elsewhere classified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06083103
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06083103 through Pure Global AI's free database. This phase not specified trial is sponsored by Institut de cancérologie Strasbourg Europe and is currently Not yet recruiting. The study focuses on Cervical Cancer. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.